Immunic, Inc. to Participate in Scientific and Industry Conferences in April ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...

Analysts at William Blair issued their FY2026 EPS estimates for shares of Immunic in a research note issued to investors on ...

Lundin Mining Announces New Shareholder Distribution Policy; Adjusting Quarterly Dividend to C$0.0275/Share From C$0.09/Share; Allocating Up to Around $150M Per Year in Share Buybacks; Committed to ...

Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...

Immunic (NASDAQ:IMUX – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to ...

Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.